AMGN Dividend History & Description — Amgen Inc
Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co. focuses its research and development on human therapeutics for the treatment of illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Co.'s principal products include ENBREL, Neulasta®, Aranesp®, Prolia®, Sensipar®/Mimpara®, XGEVA®, EPOGEN®, and NEUPOGEN®. In addition, Co. markets several other products, including KYPROLIS® (carfilzomib), Vectibix® (panitumumab), Nplate® (romiplostim), Repatha® (evolocumab), BLINCYTO® (blinatumomab), IMLYGIC® (talimogene laherparepvec) and Corlanor® (ivabradine).